Jennison Associates LLC Sells 8,370 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Jennison Associates LLC decreased its position in Twist Bioscience Co. (NASDAQ:TWST) by 25.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 24,076 shares of the company’s stock after selling 8,370 shares during the quarter. Jennison Associates LLC’s holdings in Twist Bioscience were worth $887,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. Knights of Columbus Asset Advisors LLC bought a new position in Twist Bioscience during the fourth quarter worth $2,296,000. Sumitomo Mitsui Trust Holdings Inc. increased its position in Twist Bioscience by 2.9% during the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 3,583,443 shares of the company’s stock worth $132,086,000 after acquiring an additional 99,511 shares during the period. International Assets Investment Management LLC boosted its stake in Twist Bioscience by 3,519.8% during the fourth quarter. International Assets Investment Management LLC now owns 4,018 shares of the company’s stock worth $148,000 after buying an additional 3,907 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Twist Bioscience by 354.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,674 shares of the company’s stock worth $246,000 after buying an additional 5,204 shares in the last quarter. Finally, Caprock Group LLC acquired a new stake in Twist Bioscience during the fourth quarter worth $282,000.

Analysts Set New Price Targets

A number of research firms have weighed in on TWST. The Goldman Sachs Group upgraded shares of Twist Bioscience from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $25.00 to $45.00 in a research note on Wednesday, January 17th. Barclays decreased their price target on shares of Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 10th. Finally, Scotiabank lifted their price target on shares of Twist Bioscience from $30.00 to $43.00 and gave the stock a “sector outperform” rating in a research note on Monday, February 5th.

Insider Activity

In other news, Director Robert Chess sold 4,110 shares of the business’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $34.98, for a total value of $143,767.80. Following the sale, the director now owns 64,169 shares in the company, valued at approximately $2,244,631.62. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Twist Bioscience news, CEO Emily M. Leproust sold 1,487 shares of the business’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $37.43, for a total transaction of $55,658.41. Following the completion of the sale, the chief executive officer now directly owns 516,409 shares of the company’s stock, valued at approximately $19,329,188.87. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Robert Chess sold 4,110 shares of the business’s stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $34.98, for a total value of $143,767.80. Following the sale, the director now directly owns 64,169 shares of the company’s stock, valued at $2,244,631.62. The disclosure for this sale can be found here. In the last quarter, insiders have sold 13,211 shares of company stock worth $449,573. Corporate insiders own 3.92% of the company’s stock.

Twist Bioscience Stock Performance

Shares of NASDAQ:TWST opened at $31.54 on Friday. Twist Bioscience Co. has a 52 week low of $11.46 and a 52 week high of $43.21. The company’s fifty day moving average is $34.57 and its 200-day moving average is $30.42.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Friday, February 2nd. The company reported ($0.75) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.03. Twist Bioscience had a negative net margin of 78.44% and a negative return on equity of 32.16%. The company had revenue of $71.50 million for the quarter, compared to the consensus estimate of $67.59 million. During the same quarter in the previous year, the company earned ($0.74) EPS. The firm’s revenue for the quarter was up 31.8% compared to the same quarter last year. As a group, equities research analysts anticipate that Twist Bioscience Co. will post -3.17 earnings per share for the current fiscal year.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.